PALVERAFUSP ALFA
UNII 3K7FU8FR2J

Substance Identification & Data

This profile provides standardized clinical and technical data for Palverafusp Alfa, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 3K7FU8FR2J.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2850355-87-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

3K7FU8FR2J

CAS Registry Number

2850355-87-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PALVERAFUSP ALFA

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C206964

National Cancer Institute reference terminology for clinical and research data.

INN ID

12967

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Palverafusp Alfa. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

PALVERAFUSP ALFA

Common Names & Synonyms

103-202-HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 FUSION PROTEIN WITH PEPTIDE LINKER ((GGGGS)3) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (414-ALANINE,449-ALANINE,450-ALANINE) ANTI-(HUMAN PROGRAMMED DEATH-LIGAND 1) (HUMAN-MUS MUSCULUS MONOCLONAL IMM2510 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL IMM2510 .KAPPA.-CHAIN, DIMER

HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (VEGFR-1) FRAGMENT 129-228 COMPRISING THE SECOND EXTRACELLULAR DOMAIN OF THE VEGF RECEPTOR (VEGFR-D2), (N196>A68)-VARIANT, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) (1-100 IN THE CURRENT SEQUENCE) FUSED, VIA A (G4S)3 PEPTIDE LINKER (101-115), TO GAMMA 1 HEAVY CHAIN (116-563) (VH (HOMO SAPIENS IGHV3-23*04 -(IGHD) -IGHJ4*01, CDR-KABAT (5.17.9) (146-150.165-181.214-222)) (116-233) -HOMO SAPIENS IGHG1*03 (CH1 (234-331), HINGE (332-346), CH2 S414>A, E449>A, K450>A (347-456), CH3 (457-561), CHS (562-563)) (234-563)), (336-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-12*01 -IGKJ1*01, CDRKABAT (11.7.9) (24'-34'.50'-56'.89'-97')) (1'-107') -HOMO SAPIENS IGKC*01 (108'-214')); DIMER (342-342'', 345-345'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (VEGFR-1) FRAGMENT, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), FUSED VIA A (G4S)3 PEPTIDE LINKER TO THE N-TERMINUS OF BOTH HEAVY CHAINS OF A HUMANIZED IMMUNOGLOBULIN G1-KAPPA ANTI-(HUMAN PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1, PROGRAMMED DEATH LIGAND 1, PDCD1 LIGAND 1, B7 HOMOLOG 1, B7-H1, CD274)), GLYCOFORM ALFA;

PALVERAFUSP ALFA [INN]